Across TCGA pan-cancer cohorts, SERINC4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SERINC4 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SERINC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SERINC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, MESO, and STAD are the cancer types where SERINC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.185	0.656	<.001	36	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
STAD	OS	Median	II,III,IV	0.175	0.660	.005	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SERINC4 tumor-vs-normal RNA expression · all SERINC4 data types